Navigation Links
ThromboGenics NV: Business Update
Date:5/14/2009

associated with current anti-coagulant therapy.

Patient recruitment for this trial is on track and it is anticipated that this study will conclude by the end of 2010.

TB-403 - Anti-cancer: Partnership with Roche progressing well - Phase Ib trial results expected by the end of 2009. In June 2008, ThromboGenics and its co-development partner BioInvent signed a strategic alliance deal with Roche for its novel anti-cancer agent, TB-403 (anti-PIGF). In January, 2009, ThromboGenics and BioInvent received their first success fee from Roche based on the successful transfer and implementation of technology and process development for TB-403 production. ThromboGenics received EUR3 million of the overall EUR5 million success fee.

The clinical development of TB-403 is also progressing well with the results of a Phase Ib trial expected by the end of 2009. This Phase Ib trial is assessing TB-403's tolerability, pharmacokinetics and pharmacodynamics in patients with advanced cancer.

Microplasmin for Vascular Disease - Initial partnering discussions. After the encouraging Phase II results presented last year, ThromboGenics is continuing to look for a partner to continue the further development of microplasmin for the treatment of stroke.

Pre-Clinical Highlights

Anti-VPAC - EUR3.2 million Grant Awarded to ThromboGenics for the continued development of Anti-VPAC for the treatment of thrombocytopenia - At the end of February 2009, ThromboGenics was awarded a grant of up to EUR3.2 million for the continued development of its Anti-VPAC1 (Vasoactive Intestinal Peptide/Pituitary Adenylyl Cyclase-Activating Peptide Receptor 1) antibody for the treatment of thrombocytopenia (low platelet count) after chemotherapy.

The grant was received from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) and is based on the successful completion
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart ... 2014 was a record-breaking year across the board for the ... Smart Data Platform and our Smart Data solutions, our customers ... data which led to record growth for the company in ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Pipette.com has ... to their comprehensive portfolio of Eppendorf products. , ... to purchase a Centrifuge 5424/5424 R and receive the ... either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with ... used for drug discovery to commercial manufacturing, announced today ... Next-Generation Sequencing (NGS) data packages. The NGS analysis ... ensuring the integrity of the gene, validation of the ...
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... Network is starting up a new Lake Superior ... tech economy in northwest Wisconsin. , ,WIN organizes networking ... the Wisconsin Technology Council , a state-funded adviser ... , ,Other chapters exist in Madison, Milwaukee, the Chippewa ...
... Technologies Inc., a health-care software and services company, and ... approval from Merge shareholders. , ,According to a statement ... finished on June 1 after approval by Canadian courts. ... is active in medical imaging. RIS/PACS products radiology ...
... excursions relevant to the world of Midwest technology entrepreneurs: ... the Midwest Venture Summit was held in Chicago and ... sponsored by the Chicago chapter of the Keiretsu Forum. ... to attend, an unofficial count estimated that half were ...
Cached Biology Technology:Midwest Venture Summit disappoints; Cato grades Midwest governors 2Midwest Venture Summit disappoints; Cato grades Midwest governors 3Midwest Venture Summit disappoints; Cato grades Midwest governors 4
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... has been taken by the German government to transform the ... process is gaining impetus but much remains to be done. ... is to be dramatically expanded not only through costly ... potential inland that remains to be tapped, such as in ...
... 10, 2012) − A new study just published in ... ( APNM ) reaffirms the crucial role exercise along ... disease. "Hepatocellular carcinoma (HCC) is the fifth ... deaths. Clinical and experimental studies have shown that physical ...
... of Barrett,s oesophagus (BE), a pre-cancerous condition of the lower ... time. The discovery of variations in regions on two chromosomes ... high risk of developing the disease. Although it,s been ... for BE as well as environmental ones, such as drinking ...
Cached Biology News:More accurate wind energy forecasts 2More accurate wind energy forecasts 3Researchers find first evidence for a genetic cause for Barrett's oesophagus 2Researchers find first evidence for a genetic cause for Barrett's oesophagus 3
IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
IMAGEQUANT 400 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
Biology Products: